Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Ying Han

John F Kadow

Kap-Sun Yeung

John A Bender

Piyasena Hewawasam

Katharine A Grant-Young

Kyle E Parcella

Brett R Beno

Andrew Nickel

Tao Wang

Zhongxing Zhang

Nicholas A Meanwell

Robert G Gentles

Yong Tu

Zhiwei Yin

Min Ding

Louis Stanley Chupak

Richard Pracitto

Alicia Regueiro-Ren

Thomas W Hudyma

Xiaofan Zheng

Jacob Swidorski

Zhong Yang

David J Carini

Paul Michael Scola

Lawrence G Hamann

George O Tora

Kevin W Gillman

Andrew P Degnan

Ramkumar Rajamani

Jonathan L Ditta

Derek John Denhart

Alicia Regueiro-ren

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Guanidine derivatives for the treatment of hepatitis C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both. 

NK-1 and serotonin transporter inhibitors

The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

Diketo-Piperazine and Piperidine derivatives as antiviral agents

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity useful for the treatment of HIV and AIDS. More particularly, the present disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein: 

Diketo-piperazine and piperidine derivatives as antiviral agents

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

Alkene piperidine derivatives as antiviral agents

Growing community of inventors

Cheshire, CT, United States of America

Ying Han